Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Parkinson Disease 4, Autosomal Dominant Lewy Body 9Stomach Neoplasms 3Uterine Cervical Neoplasms 2Urothelial Cancer 2Urinary Bladder Neoplasms 2Mesothelioma 2Head and Neck Neoplasms 2Carcinoma 2Various Advanced Cancer 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Small Cell Lung Carcinoma 1Ototoxicity 1Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer 1Non Small Cell Lung Cancer NSCLC 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Metastatic Urothelial Cancer 1Lung Neoplasms 1Liver Neoplasms 1Hepatoblastoma 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Bile Duct Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

pembrolizumab 3Paclitaxel 2Nivolumab 2Docetaxel 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1sacituzumab govitecan 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1Sunitinib 1Specimen Handling 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Esophageal Neoplasms × Cisplatin × Clear all
NCT03189719 2024-10-15

KEYNOTE-590

Merck Sharp & Dohme LLC

Phase 3 Completed
749 enrolled 40 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡